Aileron Therapeutics, Inc. (ALRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALRN Stock Price Chart Interactive Chart >
ALRN Price/Volume Stats
|Current price||$0.42||52-week high||$1.40|
|Prev. close||$0.40||52-week low||$0.32|
|Day high||$0.44||Avg. volume||343,613|
|50-day MA||$0.49||Dividend yield||N/A|
|200-day MA||$0.67||Market Cap||38.15M|
Aileron Therapeutics, Inc. (ALRN) Company Bio
Aileron Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of therapeutics called stapled peptides, which represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The company's lead product candidate ALRN-6924 is being evaluated in multiple clinical trials. The company was founded in 2005 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
ALRN Latest News Stream
|Loading, please wait...|
ALRN Latest Social Stream
View Full ALRN Social Stream
Latest ALRN News From Around the Web
Below are the latest news stories about Aileron Therapeutics Inc that investors may wish to consider to help them evaluate ALRN as an investment opportunity.
Investment company Morgan Jess S & Co Inc (Current Portfolio) buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Microsoft Corp, Vanguard Total International Stock, sells Amgen Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Morgan Jess S & Co Inc.
No summary available.
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Aileron Therapeutics (ALRN – Research Report), with a price target of $2.00. The company's shares closed last Wednesday at $0.59, close to its 52-week low of $0.53. According to TipRanks.com, White is a 4-star analyst with an average return of 8.9% and a 36.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics. Currently, the analyst consensus on Aileron Therapeutics is a Moderate Buy with an average price target of $3.50.
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline results in 4Q22 Dosed first 10 patients in NSCLC trial; on track to conduct blinded safety evaluation on these patients after one cycle in 1Q22 In 2021, Aileron was issued 7 new international patents, including
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held
ALRN Price Returns